Podium Presentations
Monday, May 21, 2018
11:00 AM - 12:00 PM
BREAKOUT SESSION

11:00 AM - 12:00 PM
Room: Ballroom IV (Level 400)
P1: COST-EFFECTIVENESS STUDIES
Moderator: Kenneth M. Shermock, PharmD, PhD
Director, Center for Medication Quality and Outcomes, The Johns Hopkins Hospital, Baltimore, MD, USA

CE1

11:00 AM - 11:15 AM

COST-EFFECTIVENESS OF THREE DIFFERENT STRATEGIES FOR THE TREATMENT OF FIRST RECURRENT CLOSTRIDIUM DIFFICILE INFECTION DIAGNOSED IN A COMMUNITY SETTING

Lam SW1, Delgado D2, Chalfin DB2
1Cleveland Clinic, Cleveland, OH, USA, 2Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA

CE2

11:15 AM - 11:30 AM

MANDATORY MENINGOCOCCAL SEROGROUP B VACCINATION FOR COLLEGE STUDENTS IS NOT COST-EFFECTIVE

Leeds IL1, Thayer WM2, Sankhla P3, Bamogo A3, Namasivayam V3
1Johns Hopkins University School of Medicine, Baltimore, MD, USA, 2Johns Hopkins School of Nursing, Baltimore, MD, USA, 3Johns Hopkins University Bloomberg School of Public Health, Baltimore, MD, USA

CE3

11:30 AM - 11:45 AM

COST-EFFECTIVENESS ANALYSIS OF REGORAFENIB AND TAS-102 IN REFRACTORY METASTATIC COLORECTAL CANCER

Cho SK, Hay JW, Barzi A
University of Southern California, Los Angeles, CA, USA

CE4

11:45 AM - 12:00 PM

AN ECONOMIC EVALUATION OF A FAMILIAL CANCER RISK MANAGEMENT PROGRAM FOR BRCA MUTATION CARRIERS: AN AUSTRALIAN PERSPECTIVE

Petelin L1, Liew D2, Mitchell G3, James PA3, Trainer AH3
1University of Melbourne, Parkville, Australia, 2Monash University, Melbourne, Australia, 3Peter MacCallum Cancer Centre, Parkville, Australia

11:00 AM - 12:00 PM
Room: 310 (Level 300)
P2: ADDICTION AND MENTAL HEALTH STUDIES
Moderator: Eric Slade, PhD
Research Health Scientist, University of Maryland, Baltimore, MD, USA

MH1

11:00 AM - 11:15 AM

DESCRIPTIVE RESULTS FROM THE PRESCRIPTION OPIOID MISUSE AND ABUSE QUESTIONNAIRE (POMAQ) VALIDATION STUDY

Coyne KS1, Barsdorf AI2, Poon J3, Maziere JA4, Pierson RF5, Schnoll S6, Butler SF7, Farrar JT8, Porter LN9, Franks Jr MJ10
1Evidera, Bethesda, MD, USA, 2Pfizer, Inc, New York, NY, USA, 3Eli Lilly and Company, Indianapolis, IN, USA, 4PPD, Wilmington, NC, USA, 5Janssen Global Services, LLC, Raritan, NJ, USA, 6Pinney Associates, Bethesda, MD, USA, 7Inflexxion, Inc., Waltham, MA, USA, 8University of Pennsylvania, Philadelphia, PA, USA, 9Health ResearchTx, Trevose, PA, USA, 10Naval Medical Center, Portsmouth, VA, USA

MH2

11:15 AM - 11:30 AM

ECONOMIC BURDEN OF OPIOID USE AMONG PREGNANT WOMEN: EVIDENCE FROM THE MEDICAL EXPENDITURE PANEL SURVEY, 2011-2015

Chen G, Xiao H
University of Florida, Gainesville, FL, USA

MH3

11:30 AM - 11:45 AM

GEOGRAPHIC VARIATION OF HIGH-RISK OPIOID USE AND RISK OF OVERDOSE AMONG DISABLED MEDICARE BENEFICIARIES IN THE US FROM 2011 TO 2015

Lo-Ciganic W1, Gellad WF2, Zhou L3, Donohue JM4, Roubal A5, Hines L6, Lindermann J7, Malone DC3, Bhattacharjee S3, Lee JK3, Kwoh CK3
1The University of Arizona, Tucson, AZ, USA, 2Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare System, Pittsburgh, PA, USA, 3University of Arizona, Tucson, AZ, USA, 4University of Pittsburgh, Pittsburgh, PA, USA, 5Robert Wood Johnson Foundation, Princeton, NJ, USA, 6Pharmacy Quality Alliance, Springfield, VA, USA, 7ESRI Inc., Broomfield, CO, USA

MH4

11:45 AM - 12:00 PM

EXAMINING PARKINSON’S DISEASE PSYCHOSIS TREATMENT OUTCOMES IN THE REAL WORLD: THE INSYTE OBSERVATIONAL STUDY

Goldman J1, Fredericks D2, Trotter J3, Heywood C3, Ryan A3, Block S3, Rattana S3, Shim A2, Larsen N2
1Rush University Medical Center, Chicago, IL, USA, 2ACADIA Pharmaceuticals Inc., San Diego, CA, USA, 3Continuum Clinical, Northbrook, IL, USA
3:45 PM - 4:45 PM
BREAKOUT SESSION

3:45 PM - 4:45 PM
Room: 309 (Level 300)
P3: MEDICAL DEVICE AND DIAGNOSTICS STUDIES
Moderator: Jan Pietzsch, PhD
President & Chief Executive Officer, Wing Tech Inc., Irvine, CA, USA

MD1

3:45 PM - 4:00 PM

A REAL-WORLD ASSESSMENT OF THE CLINICAL AND ECONOMIC IMPACT OF POWERED VS MANUAL ENDOSCOPIC STAPLERS WHEN USED IN CONJUNCTION WITH BUTTRESS IN BARIATRIC SURGERY

Lim S1, Roy S1, Yadalam S2, Johnston SS3
1Ethicon Inc, Somerville, NJ, USA, 2Johnson & Johnson Co., New Brunswick, NJ, USA, 3Johnson & Johnson, Inc., New Brunswick, NJ, USA

MD2

4:00 PM - 4:15 PM

A COMPARISON OF LONG-TERM PATIENT OUTCOMES AFTER HEART VALVE REPLACEMENT WITH BIOLOGICAL OR MECHANICAL VALVES IN MEDICARE BENEFICIARIES

Du D1, Lu X1, McKean S2, Warnock R2, Laschinger J1, Loyo-Berríos N1, Marinac-Dabic D1
1U.S. Food and Drug Administration, Silver Spring, MD, USA, 2Acumen LLC, Burlingame, CA, USA

MD3

4:15 PM - 4:30 PM

LINKAGE BETWEEN ORTHOPEDIC REGISTRY AND ADMINISTRATIVE DATA USING INDIRECT IDENTIFIERS FOR NATIONAL DEVICE INFRASTRUCTURE DEVELOPMENT

Mao J1, Etkin C2, Lewallen DG3, Sedrakyan A4
1Weill Cornell Medical College, New York, NY, USA, 2American Joint Replacement Registry, Rosemont, IL, USA, 3Mayo Clinic, Rochester, MN, USA, 4Weill Cornell Medicine, New York, NY, USA

MD4

4:30 PM - 4:45 PM

PAYER COVERAGE AND EVIDENCE REQUIREMENTS FOR ONCOLOGY LIQUID BIOPSY TESTING IN THE UNITED STATES: CURRENT STATE AND FILLING THE GAPS

Spinner DS1, Faulkner EC2, Ringo MC2, Mihos MC1, Joines J3
1Evidera, Chapel Hill, NC, USA, 2Evidera, Raleigh, NC, USA, 3PPD, Raleigh, NC, USA

3:45 PM - 4:45 PM
Room: 310 (Level 300)
P4: BENEFITS, VALUE, AND COVERAGE STUDIES
Moderator: Ya-Chen Tina Shih, PhD
Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

VA1

3:45 PM - 4:00 PM

DOES THE TIMING OF A DRUG’S COSTS AND BENEFITS INFLUENCE US PAYER COVERAGE OF SPECIAL DRUGS?

Kim DD, Chambers J, Pope E, Cohen JT, Neumann PJ
Tufts Medical Center, Boston, MA, USA

VA2

4:00 PM - 4:15 PM

TRENDS IN THE ECONOMIC VALUE OF NEWLY APPROVED CANCER THERAPIES IN THE U.S.

Chen AJ1, Hu X1, Jena AB2, Goldman DP1
1University of Southern California, Los Angeles, CA, USA, 2Harvard Medical School, Boston, MA, USA

VA3

4:15 PM - 4:30 PM

“IT’S TOUGH TO MAKE PREDICTIONS, ESPECIALLY ABOUT THE FUTURE”: COMPARING LIFE EXPECTANCY PREDICTIONS BASED ON PERIOD VERSUS COHORT LIFE TABLES

Garrison LP, Li M
University of Washington, Seattle, WA, USA

VA4

4:30 PM - 4:45 PM

ECONOMIC CONSEQUENCES OF ANTI-HCV ANTIVIRAL TREATMENT INVESTMENT FROM THE NHS PERSPECTIVE

Mennini FS1, Marcellusi A1, Viti R1, Kondili L2, Rosato S2, Vella S2, on behalf of PITER collaboration study group .2
1Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 2Center for Global Health, Istituto Superiore di Sanità, Rome, Italy
5:00 PM - 6:00 PM
BREAKOUT SESSION

5:00 PM - 6:00 PM
Room: 309 (Level 300)
P5: COST STUDIES
Moderator: C. Edward Chou, PhD
Associate Professor, Auburn University, Auburn, AL, USA

CS1

5:00 PM - 5:15 PM

WITHDRAWN

CS2

5:15 PM - 5:30 PM

CLINICAL, HUMANISTIC, AND ECONOMIC BURDEN OF OSTEOARTHRITIS (OA) AMONG NONINSTITUTIONALIZED ADULTS IN THE UNITED STATES (US)

Zhao X1, Shah D1, Gandhi K2, Wei W3, Dwibedi N1, Webster L4, Sambamoorthi U5
1West Virginia University, School of Pharmacy, Morgantown, WV, USA, 2Teva Pharmaceutical Industries, Frazer, PA, USA, 3Regeneron Pharmaceuticals, Tarrytown, NY, USA, 4PRA Health Sciences, Salt Lake City, UT, USA, 5West Virginia University, Morgantown, WV, USA

CS3

5:30 PM - 5:45 PM

PROJECTED MEDICARE SAVINGS ASSOCIATED WITH LOWERING THE RISK OF TOTAL HIP ARTHROPLASTY REVISION: AN ADMINISTRATIVE CLAIMS DATABASE ANALYSIS

Ackerman SJ1, Knight T2, Wahl PM2
1Covance Market Access Services Inc., San Diego, CA, USA, 2Covance Market Access Services Inc., Gaithersburg, MD, USA

CS4

5:45 PM - 6:00 PM

ALZHEIMER’S ATTRIBUTABLE COSTS IN THE UNITED STATES: A SECONDARY ANALYSIS OF MEDICAL EXPENDITURE PANEL SURVEY 2011-2015

Shuvo TA, Haider MR, Khan MM
University of South Carolina, Columbia, SC, USA

5:00 PM - 6:00 PM
Room: 310 (Level 300)
P6: ANALYTIC AND MODELING METHODS
Moderator: Michael Eaddy, PharmD, PhD
Vice President, Xcenda, Palm Harbor, FL, USA

MO1

5:00 PM - 5:15 PM

UNITED STATES VALUATION OF EQ-5D-5L HEALTH STATES: AN INITIAL MODEL USING A STANDARDIZED PROTOCOL

Pickard AS1, Law EH1, Jiang R1, Oppe M2, Shaw JW3, Xie F4, Boye KS5, Gong CL6, Chapman RH7, Balch A8
1University of Illinois at Chicago, Chicago, IL, USA, 2EuroQol Research Foundation, Rotterdam, The Netherlands, 3Bristol-Myers Squibb, Lawrenceville, NJ, USA, 4McMaster University, Hamilton, ON, Canada, 5Eli Lilly and Company, Indianapolis, IN, USA, 6University of Southern California, Los Angeles, CA, USA, 7Institute for Clinical and Economic Review, Boston, MA, USA, 8Patient Advocate Foundation, Hampton, VA, USA

MO2

5:15 PM - 5:30 PM

A PREDICTION MODEL FOR LENGTH OF STAY IN THE ICU AMONG SEPTIC PATIENTS: A MACHINE LEARNING APPROACH

Ling Y1, Chen Y2, Chirikov V1, Xie J3, Qiu H3, Otgonsuren Z1, Dong P2, Gao X1
1Pharmerit International, Bethesda, MD, USA, 2Pfizer Investment Co., Ltd., Beijing, China, 3Zhongda Hospital, Nanjing, China

MO3

5:30 PM - 5:45 PM

IDENTIFYING AND ASSESSING THE FEASIBILITY OF PROPOSED ALTERNATIVE APPROACHES TO QALY ESTIMATION WITHIN COST-EFFECTIVENESS MODELS USING A SYSTEMATIC LITERATURE REVIEW

Brouwer E, Carlson JJ
University of Washington, Seattle, WA, USA

MO4

5:45 PM - 6:00 PM

GLOBALIZATION MODULE FOR A DIABETES PROGRESSION PREDICTION MODEL: THE BUILDING, RELATING, ACTING, AND VALIDATING OUTCOMES (BRAVO) MODEL

Shao H1, Yang S2, Fonseca V3, Shi L1
1Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA, 2Louisiana State University Health Science Center, New Orleans, LA, USA, 3Tulane University School of Medicine, New Orleans, LA, USA
Tuesday, May 22, 2018
11:00 AM - 12:00 PM
BREAKOUT SESSION

11:00 AM - 12:00 PM
Room: 309 (Level 300)
P7: CANCER STUDIES
Moderator: Brian Seal, PhD, RPh, MBA
Senior Director HEOR, Astra Zeneca, Gaithersburg, MD, USA

CN1

11:00 AM - 11:15 AM

ECONOMIC GUIDANCE PANEL CHANGES TO MINIMIZE POST-PROGRESSION TREATMENT EFFECTS BY THE PAN-CANADIAN ONCOLOGY DRUG REVIEW IN ECONOMIC EVALUATIONS ASSESSING CANCER DRUGS

Samjoo I, Whitney S, Grima A, Grima D
Cornerstone Research Group, Burlington, ON, Canada

CN2

11:15 AM - 11:30 AM

ESTIMATING THE IMPACT OF AFFORDABLE CARE ACT (ACA) ON LIKELIHOOD OF RECEIVING MAMMOGRAPHY AND PAP SMEAR SCREENINGS

Alharbi A, Khan MM
University of South Carolina, Columbia, SC, USA

CN3

11:30 AM - 11:45 AM

HEALTH-RELATED QUALITY OF LIFE ASSESSMENTS PREDICT RELAPSE OR DEATH IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM THE CONNECT® MM REGISTRY

Wagner I1, Durie BG2, Jagannath S3, Narang M4, Terebelo HR5, Gasparetto C6, Toomey K7, Hardin JW8, Kitali A9, Yue L9, Agarwal A9, Srinivasan S9, Flick ED9, Rifkin RM10, Abonour R11
1Wake Forest University School of Medicine, Winston-Salem, NC, USA, 2Cedars-Sinai Samuel Oschin Cancer Institute, Los Angeles, CA, USA, 3Mount Sinai Hospital, New York, NY, USA, 4Maryland Oncology Hematology, Columbia, MD, USA, 5Providence Hospital and Medical Center, Southfield, MI, USA, 6Duke Cancer Institute, Durham, NC, USA, 7Steeplechase Cancer Center, Somerville, NJ, USA, 8University of South Carolina, Columbia, SC, USA, 9Celgene Corporation, Summit, NJ, USA, 10US Oncology Research and Rocky Mountain Cancer Centers, Denver, CO, USA, 11Simon Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA

CN4

11:45 AM - 12:00 PM

PROJECTING OVERALL SURVIVAL (OS) WITH IMMUNO-ONCOLOGY (IO) TREATMENTS: APPLICATION OF ALTERNATIVE APPROACHES IN METASTATIC MERKEL CELL CARCINOMA (MMCC)

Proskorovsky I1, Lanitis T2, Ambavane A2, Hunger M3, Bharmal M4, Zheng Y5, Phatak H5
1Evidera, Montreal, QC, Canada, 2Evidera, London, UK, 3Mapi, an ICON plc company, Munich, Germany, 4Merck KGaA, Darmstadt, Germany, 5EMD Serono Inc., Rockland, MA, USA

11:00 AM - 12:00 PM
Room: 310 (Level 300)
P8: CARDIOVASCULAR STUDIES
Moderator: Jay Lin, PhD, MBA
Managing Director, Novosys Health, Green Brook, NJ, USA

CV1

11:00 AM - 11:15 AM

NON-INFERIORITY CLINICAL TRIAL DESIGN, DRUG APPROVAL, AND IMPLICATIONS FOR CLINICIANS IN PRESCRIBING ORAL ANTICOAGULANTS

Choi YC1, Vo TN1, Carlson AM2
1University of Minnesota, Minneapolis, MN, USA, 2Data Intelligence Consultants, LLC, Eden Prairie, MN, USA

CV2

11:15 AM - 11:30 AM

SECONDARY PREVENTION USING CHOLESTEROL-LOWERING MEDICATIONS IN PATIENTS MEETING NEW TREATMENT GUIDELINES: A RETROSPECTIVE COHORT ANALYSIS

Han X1, McCombs JS1, Fox DS1, Chu M1, Dougherty JS2
1University of Southern California, Los Angeles, CA, USA, 2PhRMA, Washington, DC, USA

CV3

11:30 AM - 11:45 AM

COMPARATIVE EFFECTIVENESS OF DIRECT ORAL ANTICOAGULANTS VERSUS WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION

Done N1, Li D1, Woolley A2, Rose AJ3, Prentice JC1
1Veterans Health Administration, Boston, MA, USA, 2Bouve College of Health Sciences, Boston, MA, USA, 3RAND Corporation, Boston, MA, USA

CV4

11:45 AM - 12:00 PM

ADHERENCE TO SELF-CARE RECOMMENDATIONS AND ASSOCIATED FACTORS AMONG ADULT HEART FAILURE PATIENTS AT GONDAR UNIVERSITY REFERRAL HOSPITAL, NORTHWEST ETHIOPIA.

Seid MA
University of Gondar, Gondar, Ethiopia
3:45 PM - 4:45 PM
BREAKOUT SESSION

3:45 PM - 4:45 PM
Room: 309 (Level 300)
P9: HEALTH TECHNOLOGY ASSESSMENT STUDIES
Moderator: Andrew Briggs, DPhil bio
Professor, University of Glasgow, Glasgow, Scotland, UK

HT1

3:45 PM - 4:00 PM

SIMILARITIES AND DIFFERENCES IN EUROPEAN HTA EVIDENCE REQUIREMENTS: ONE FOR ALL OR ONE FOR NONE?

Mordin M1, Fernandez MM2, Pearson I3, Copley-Merriman C1, McBride D3
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3RTI Health Solutions, Manchester, UK

HT2

4:00 PM - 4:15 PM

A HOLISTIC APPROACH TO EVALUATE THE COST-EFFECTIVENESS OF PEMBROLIZUMAB WITH MULTIPLE INDICATIONS: A NORWAY-BASED EXAMPLE

Wu E1, Pellissier J2, Kvamme M3, Irgens K3
1Merck, North Wales, PA, USA, 2Merck & Co., Inc., North Wales, PA, USA, 3MSD Norge A/S, Drammen, Norway

HT3

4:15 PM - 4:30 PM

USING REAL-WORLD EVIDENCE FOR HEALTH TECHNOLOGY ASSESSMENT SUBMISSIONS: LESSONS AND INSIGHTS FROM REVIEW OF NICE’S TECHNOLOGY ASSESSMENT REPORTS (2016-2017)

Aggarwal S1, Topaloglu O1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

HT4

4:30 PM - 4:45 PM

HEALTH TECHONOLGY ASSESSMENT (HTA) AGENCIES CONSIDERATION OF REAL WORLD EVIDENCE (RWE)

Jao R1, Jaksa A1, Pontynen A1, Wang X2
1Context Matters, New York, NY, USA, 2Celgene Corporation, Summit, NJ, USA

3:45 PM - 4:45 PM
Room: Ballroom II (Level 400)
P10: HEALTHCARE UTILIZATION AND OUTCOMES STUDIES
Moderator: Ebere Onukwugha, MS, PhD 
Associate Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA

HU1

3:45 PM - 4:00 PM

ANNUAL CHANGE IN CONTROLLED SUBSTANCE OPIOID PRESCRIBING AND CONCOMITANT MEDICATIONS FROM AN URBAN ACADEMIC EMERGENCY DEPARTMENT FROM 2011 – 2016

Voelker J1, Crawford A1, Sabonjian M2, Maio V3, Mammen P2
1Jefferson College of Population Health at Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA, 3Thomas Jefferson University, Philadelphia, PA, USA

HU2

4:00 PM - 4:15 PM

COGNITIVE DECLINE WITH ANTICHOLINERGIC MEDICATION USE AMONG ELDERLY NURSING HOME RESIDENTS WITH DEPRESSION

Aparasu RR1, Chatterjee S2, Johnson ML3, Chen H3, Carnahan R4
1Department of Pharmaceutical Health Outcomes and Policy, Houston, TX, USA, 2Novartis Healthcare Pvt Ltd, Hyderabad, India, 3College of Pharmacy, University of Houston, Houston, TX, USA, 4University of Iowa, Iowa City, IA, USA

HU3

4:15 PM - 4:30 PM

INITIATION OF PSYCHOTROPIC PRESCRIPTIONS WITHOUT A PSYCHIATRIC DIAGNOSIS IN US ADULTS

Rhee TG1, Rosenheck RA2
1Yale University School of Medicine, New Haven, CT, USA, 2Yale University School of Medicine, West Haven, CT, USA

HU4

4:30 PM - 4:45 PM

THE USE OF MACHINE LEARNING TO BOOST IDENTIFICATION OF ATRIAL FIBRILLATION AND INCREASE APPROPRIATE UTILIZATION OF ANTICOAGULANT DRUGS

Hertzberg J, Forni A
Optum, Minnetonka, MN, USA
5:00 PM - 6:00 PM
BREAKOUT SESSION

5:00 PM - 6:00 PM
Room: 309 (Level 300)
P11: MEDICATION ADHERENCE STUDIES
Moderator: Julia Slejko, PhD, BA
Assistant Professor, University of Maryland School of Pharmacy, Baltimore, MD, USA

AD1

5:00 PM - 5:15 PM

THE ASSOCIATION BETWEEN ANTI-EPILEPTIC DRUG ADHERENCE TO SODIUM CHANNEL BLOCKERS AND HEALTH-RELATED QUALITY OF LIFE: ANALYSIS OF US SURVEY DATA FROM PATIENTS WITH EPILEPSY

Lee LK1, Rajagopalan K2
1Kantar Health, San Mateo, CA, USA, 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA

AD2

5:15 PM - 5:30 PM

MODIFIED DRUG ADHERENCE WORK-UP (M-DRAW) TOOL IN PATIENTS WITH DIABETES AT VETERANS AFFAIRS HEALTH SYSTEM: TOOL VALIDATION AND PRELIMINARY RESULT

Lee S1, Gogineni H1, Bae-Shaaw Y2, Worley M3, Law A1
1Western University of Health Sciences, Pomona, CA, USA, 2University of Southern California, Los Angeles, CA, USA, 3Ohio State University, Columbus, OH, USA

AD3

5:30 PM - 5:45 PM

ADHERENCE ISSUES IN FIBROMYALGIA: HOW CAN ACCEPTANCE MEASUREMENT HELP UNDERSTANDING PATIENTS' CONCERNS AND WORKING ON SOLUTIONS?

Wiederkehr S1, de Bock E1, Chekroun M2, Arnould B1
1Mapi, An ICON plc Company, Patient-Centered Outcomes, Lyon, France, 2Carenity, Paris, France

AD4

5:45 PM - 6:00 PM

DISCONTINUATION, SWITCHING AND RESTARTING AMONG MIGRAINE PATIENTS INITIATING PROPHYLAXIS

Bonafede MM1, Wilson KL1, Xue F2, Chia VM3, Porter JK4, Desai P2
1Truven Health Analytics, an IBM Company, Cambridge, MA, USA, 2Amgen Inc., Thousand Oaks, CA, USA, 3Amgen Inc, Thousand Oaks, CA, USA, 4Amgen (Europe) GmbH, Zug, Switzerland

5:00 PM - 6:00 PM
Room: 310 (Level 300)
P12: COST-EFFECTIVENESS ANTIVIRAL STUDIES
Moderator: Sonya J. Snedecor, PhD
Executive Director, Health Economics, Pharmerit International, Bethesda, MD, USA

AV1

5:00 PM - 5:15 PM

COST-EFFECTIVENESS OF STAGED DIRECT-ACTING ANTIVIRAL TREATMENT POLICIES IN AN INTEGRATED HEALTHCARE SYSTEM

Karmarkar T1, Gaskin DJ1, Rodriguez CV2, Padula WV1
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Kaiser Permanente, Rockville, MD, USA

AV2

5:15 PM - 5:30 PM

COST-EFFECTIVENESS ANALYSIS OF BASELINE TESTING FOR RESISTANCE-ASSOCIATED POLYMORPHISMS TO OPTIMISE TREATMENT DURATION IN GENOTYPE 1 NON-CIRRHOTIC TREATMENT-NAÏVE PATIENTS WITH CHRONIC HEPATITIS C VIRUS

Fawsitt CG1, Vickerman P1, Cooke G2, Welton NJ1
1University of Bristol, Bristol, UK, 2Imperial College London, London, UK

AV3

5:30 PM - 5:45 PM

DOLUTEGRAVIR AND RILPIVIRINE TO TREAT VIROLOGICALLY SUPPRESSED ADULTS LIVING WITH HIV-1: A CANADIAN COST-UTILITY ANALYSIS

Arthurs E1, Ward T2, Darlington O2, Sugrue D2, Martin AA3, Cartier SE4, Lee A4, Becker DL4, Punekar YS5, McEwan P2
1GSK, Mississauga, ON, Canada, 2Health Economics & Outcomes Research Ltd, Cardiff, UK, 3GSK, Uxbridge, UK, 4Optum, Burlington, ON, Canada, 5ViiV Healthcare, Brentford, Middlesex, UK

AV4

5:45 PM - 6:00 PM

COST-EFFECTIVENESS ANALYSIS OF UNIVERSAL VS TARGETED HUMAN IMMUNODEFICIENCY VIRUS (HIV) SCREENING APPROACHES TO IDENTIFY NEW HIV DIAGNOSES IN THE EMERGENCY DEPARTMENT (ED)

Batista AE1, Bartolome L1, Nelson F2, Maio V1, Mammen P2
1Thomas Jefferson University, Philadelphia, PA, USA, 2Thomas Jefferson University Hospital, Philadelphia, PA, USA
Wednesday, May 23, 2018
8:30 AM - 9:30 AM
BREAKOUT SESSION

8:30 AM - 9:30 AM
Room: 309 (Level 300)
P13: CONCEPTUAL PAPERS
Moderator: Karen Rascati, RPh, PhD
Professor, The University of Texas College of Pharmacy, Austin, TX, USA

CP1

8:30 AM - 8:45 AM

AN ANALYTICAL FRAMEWORK FOR ECONOMIC EVALUATION OF INTERVENTIONS WITH EFFECTS ON MULTIPLE OUTCOMES, COSTS FALLING ON DIFFERENT BUDGETS, AND INVOLVING MORE THAN ONE DECISION MAKER

Griffin S1, Walker S2, Sculpher M1, Asaria M2
1University of York, York, UK, 2University of York, Heslington, York, UK

CP2

8:45 AM - 9:00 AM

GRAPHICAL PROBABILISTIC MODELS FOR RISK PREDICTION AND DECISION MAKING USING REAL-WORLD DATA: A DEVELOPING TOOL FOR THE ERA OF PRECISION MEDICINE

Arora P1, Boyne DJ2, Druzdzel MJ3
1Lighthouse Outcomes, Toronto, ON, Canada, 2University of Calgary, Calgary, ON, Canada, 3University of Pittsburgh, Pittsburgh, PA, USA

CP3

9:00 AM - 9:15 AM

ASSESSMENT-TIME BIAS: STATISTICAL APPROACHES TO ADJUSTING FOR BETWEEN-TRIAL DIFFERENCES IN THE SCHEDULE OF ASSESSMENT FOR DISEASE PROGRESSION IN IMMUNO-ONCOLOGY TRIALS

Kapetanakis V1, Schlichting M2, Stevens JW3, Prawitz T1, Kearney M4, Phatak H5, Benedict A6, Bharmal M4
1Evidera, London, UK, 2Global Biostatistics and Epidemiology, Merck KGaA, Darmstadt, Germany, 3Reader in Decision Science, University of Sheffield, Sheffield, UK, 4Global Evidence & Value Development, Merck KGaA, Darmstadt, Germany, 5EMD Serono, Rockland, MA, USA, 6Evidera, Budapest, Hungary

CP4

9:15 AM - 9:30 AM

BUDGET IMPACT ANALYSIS WITH SIMULTANEOUS MULTIPLE MARKET ENTRANTS: STATIC VERSUS DYNAMIC BASELINE MARKET SHARES

O'Day K, Meyer K
Xcenda, Palm Harbor, FL, USA

8:30 AM - 9:30 AM
Room: 310 (Level 300)
P14: HEALTHCARE RESOURCE USE AND EXPENDITURE STUDIES
Moderator: Brian Rittenhouse
Associate Professor, Massachusetts College of Pharmacy and Health Sciences (MCPHS) University, Boston, MA, USA

HE1

8:30 AM - 8:45 AM

EFFECT OF A PROVIDER-FOCUSED ASTHMA CARE QUALITY IMPROVEMENT PROGRAM ON PATIENT-LEVEL ASTHMA-RELATED HEALTH CARE COSTS

Rojanasarot S, Carlson AM, St. Peter WL, Schommer JC
College of Pharmacy, University of Minnesota, Minneapolis, MN, USA

HE2

8:45 AM - 9:00 AM

HEALTH CARE COSTS IN DIABETES: THE ROLE OF COMORBIDITY TYPE

Lin P1, Pope E1, Zhou FL2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Sanofi, Bridgewater, NJ, USA

HE3

9:00 AM - 9:15 AM

A TALE OF TWO UNIVERSAL HEALTH INSURANCE SCHEMES IN ONE COUNTRY: HORIZONTAL INEQUALITY OF GOVERNMENT MEDICAL AND PHARMACEUTICAL BENEFITS FOR AUSTRALIAN CHILDREN

Huang L, Clarke P, Dalziel K
The University of Melbourne, Melbourne, Australia

HE4

9:15 AM - 9:30 AM

REAL-WORLD ANALYSIS OF TREATMENT PATTERNS AND LONG-TERM EFFECTIVENESS AMONG PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS OF LUNG ORIGIN (LUNG NET): A MULTICENTER STUDY

Dasari A1, Bergsland EK2, Benson AB3, Cai B4, Huynh L5, Totev T5, Shea J5, Duh MS5, Neary MP4, Kulke MH6
1University of Texas MD Anderson Cancer Center, Houston, TX, USA, 2UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA, 3Northwestern University Feinberg School of Medicine, Chicago, IL, USA, 4Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 5Analysis Group, Inc., Boston, MA, USA, 6Dana-Farber Cancer Institute, Boston, MA, USA
1:45 PM - 2:45 PM
BREAKOUT SESSION

1:45 PM - 2:45 PM
Room: Ballroom III (Level 400)
P15: UTILITY AND PATIENT PREFERENCE STUDIES
Moderator: John E. Brazier, PhD, FMedSci
Professor of Health Economics and Dean of ScHARR, University of Sheffield, Sheffield, UK

PP1

1:45 PM - 2:00 PM

PATIENT PREFERENCES FOR HEALTH STATES FOLLOWING ALTERNATIVE MANAGEMENT OPTIONS FOR DUCTAL CARCINOMA IN SITU

Campbell BM1, Yang J2, Gonzalez JM2, Reed SD2, Havrilesky L3, Johnson FR2, Hwang ES3
1Duke University School of Medicine, Durham, NC, USA, 2Duke Clinical Research Institute, Durham, NC, USA, 3Duke Cancer Insitute, Durham, NC, USA

PP2

2:00 PM - 2:15 PM

CHOICE DEFINES QALYS: A US VALUATION OF THE EQ-5D-5L

Craig BM1, Rand K2
1University of South Florida, and Assistant Member, Health Outcomes and Behavior, Moffitt Cancer Center, Tampa, FL, USA, 2University of Oslo, Oslo, Norway

PP3

2:15 PM - 2:30 PM

ESTIMATING THE HEALTH STATE UTILITY OF PATIENTS WITH HER2– GBRCA+ METASTATIC BREAST CANCER TREATED WITH OLAPARIB OR CHEMOTHERAPY VIA A MAPPING ANALYSIS OF EORTC QLQ-C30 DATA COLLECTED IN THE OLYMPIAD CLINICAL TRIAL

Robson M1, Hettle R2, Degboe A3, Saunders O4, Cain T4, Kilvert H4, Johnson H4
1Memorial Sloan Kettering Cancer Center, New York, NY, USA, 2AstraZeneca, Cambridge, UK, 3AstraZeneca, Gaithersburg, MD, USA, 4Bresmed Ltd, Sheffield, UK

PP4

2:30 PM - 2:45 PM

CONSUMER PREFERENCES FOR PRECISION MEDICINE TECHNOLOGIES: EVIDENCE FROM A DISCRETE CHOICE EXPERIMENT

Regier DA1, Veenstra DL2, Basu A3, Saha J2, Carlson JJ3
1BC Cancer/University of British Columbia, Vancouver, BC, Canada, 2Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA
3:00 PM - 4:00 PM
BREAKOUT SESSION

3:00 PM - 4:00 PM
Room: 309 (Level 300)
P16: INFECTIOUS DISEASE AND RESPIRATORY STUDIES
Moderator: Fadia T. Shaya, PhD, MPH
Professor and Vice-Chair for Academic Affairs PHSR, University of Maryland School of Pharmacy, Baltimore, MD, USA

IN1

3:00 PM - 3:15 PM

USING ELECTRONIC HEALTH RECORDS TO EXAMINE HPV VACCINE INITIATION AND COMPLETION RATES

Yu J, Buikema AR, Togun A
Optum, Eden Prairie, MN, USA

IN2

3:15 PM - 3:30 PM

LONG-TERM HEALTH BENEFIT OF IBALIZUMAB IN THE TREATMENT OF ADULTS WITH MULTIDRUG-RESISTANT HIV-1 INFECTION

Brogan AJ1, Talbird SE2, Davis AE2, La EM2, Miao Z3, Lewis S4
1RTI Health Solutions, Didsbury, Manchester, UK, 2RTI Health Solutions, Research Triangle Park, NC, USA, 3Theratechnologies Inc., Montréal, QC, Canada, 4TaiMed Biologics, Irvine, CA, USA

IN3

3:30 PM - 3:45 PM

INCIDENCE OF HEPATOCELLULAR CARCINOMA AND EXTRAHEPATIC CANCERS AMONG HCV-INFECTED PATIENTS IN THE ERA OF DIRECT-ACTING ANTIVIRALS

Wang W1, Lo Re III V2, Xiao H1, Brown J1, Yi G1, Park H1
1University of Florida, Gainesville, FL, USA, 2University of Pennsylvania, Philadelphia, PA, USA

IN4

3:45 PM - 4:00 PM

ESTIMATING THE CURRENT COST OF ENDOSCOPIC SINUS SURGERY IN THE US – A CLAIMS-BASED APPROACH

Velez FF1, Sacks H1, Messina J1, Kozma CM2, Malone D3, Mahmoud R1
1OptiNose US, Inc., Yardley, PA, USA, 2CK Consulting Associates, LLC, Saint Helena Island, SC, USA, 3University of Arizona, Tucson, AZ, USA

3:00 PM - 4:00 PM
Room: 310 (Level 300)
P17: NEUROLOGICAL CONDITIONS STUDIES
Moderator: Michael T. Halpern, MD, PhD, MPH
Associate Professor, Temple University College of Public Health, Philadelphia, PA, USA

ND1

3:00 PM - 3:15 PM

USE OF DISEASE MODIFYING AGENTS IN PATIENTS WITH MULTIPLE SCLEROSIS: ANALYSIS OF TEN YEARS OF NATIONAL DATA

Earla JR1, Paranjpe R1, Kachru N2, Aparasu RR1
1University of Houston, Houston, TX, USA, 2Gilead Sciences Inc., Foster City, CA, USA

ND2

3:15 PM - 3:30 PM

HOW PRESCRIPTION DRUG COST FOR DISEASE MODIFYING THERAPY (DMT) IMPACTS OVERALL HEALTH CARE SPENDING AMONG INDIVIDUALS WITH MULTIPLE SCLEROSIS

Kim Y1, Krause TM1, Freeman L2
1The University of Texas Health Science Center at Houston School of Public Health, Houston, TX, USA, 2The University of Texas Health Science Center at Houston McGovern Medical School, Houston, TX, USA

ND3

3:30 PM - 3:45 PM

PRODUCTIVITY LOSSES AMONG PATIENTS WITH MIGRAINE: AN ANALYSIS OF ERENUMAB CLINICAL TRIAL DATA

Porter JK1, Di Tanna GL1, Lipton RB2, Sapra S3, Villa G1
1Amgen (Europe) GmbH, Zug, Switzerland, 2Albert Einstein College of Medicine, Bronx, NY, USA, 3Amgen Inc, Thousand Oaks, CA, USA

ND4

3:45 PM - 4:00 PM

COST-UTILITY ANALYSIS COMPARING ABOBOTULINUMTOXINA WITH ONABOTULINUMTOXINA FOR THE TREATMENT OF PEDIATRIC LOWER LIMB SPASTICITY

Johnston KM1, Hansen RN2, Cheung A1, Liovas A3, Armstrong A3, Danchenko N4, Bains S5, Dinet J4, Sullivan SD2
1Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada, 2University of Washington, Seattle, WA, USA, 3Ipsen Biopharmaceuticals Canada, Mississauga, ON, Canada, 4Ipsen Global, Boulogne-Billancourt, France, 5Ipsen US, Basking Ridge, NJ, USA
Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.